diaphorase/breast neoplasms

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 50 rezilta yo

DT-diaphorase and cytochrome B5 reductase in human lung and breast tumours.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The level of expression of enzymes that can activate or detoxify bioreductive agents within tumours has emerged as an important feature in the development of these anti-tumour compounds. The levels of two such reductase enzymes have been determined in 19 human non-small-cell lung tumours and 20

Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Bioreductive antitumor quinones require reductive metabolism to produce their cytotoxic effects. A series of these compounds was screened for relative rates of reduction by the two-electron reductase, NAD(P)H:quinone oxidoreductase (DTD). The antitumor quinones streptonigrin (SN),

Demonstration of the activation of prodrug CB 1954 using human DT-diaphorase mutant Q104Y-transfected MDA-MB-231 cells and mouse xenograft model.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The rat form of DT-diaphorase (NAD(P)H: quinone acceptor oxidoreductase; EC 1.6.99.2) is more effective than the human form in activating prodrugs such as CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide). Our site-directed mutagenesis study has revealed that residue 104 (Tyr in the rat enzyme and

The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233).

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To determine the dependency of the aerobic and hypoxic toxicity of tirapazamine on the intracellular activity of DT-diaphorase. METHODS A panel of 18 human cell lines comprising predominantly small cell and nonsmall cell lung cancer and breast cancer lines were used. The activity of

Histopathological and immunohistochemical evaluations of breast cancer treated with radiofrequency ablation.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Although RF ablation is a promising non-surgical ablation technique for the treatment of breast cancer, assessment of the efficacy requires not only imaging of tumor necrosis but also histological confirmation. METHODS Two series of patients were treated with RF ablation. In the first

Use of cytokeratin 8 immunohistochemistry for assessing cell death after radiofrequency ablation of breast cancers.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The effects of minimally invasive therapies such as radiofrequency ablation (RFA) and laser induced thermal therapy on breast carcinoma lesions usually is assessed by NADH diaphorase enzyme histochemistry for cell viability. NADH staining requires frozen material, however, with its associated poor

Heat fixation of cancer cells ablated with high-intensity-focused ultrasound in patients with breast cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND High-intensity-focused ultrasound (HIFU) is a noninvasive thermal ablation technique. This study reports the use of histological techniques for the pathological assessment of HIFU effects in patients with breast cancer. METHODS Twenty-three patients with biopsy-proven breast cancer

NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

NAD(P)H:Quinone Oxidoreductase1 (NQO1) also known as DT-diaphorase is a flavoprotein that catalyzes the two-electron reduction of quinones, quinone imines and azo-dyes and thereby protects cells against mutagenicity and carcinogenicity resulting from free radicals and toxic oxygen metabolites

Radiofrequency ablation of breast cancer: first report of an emerging technology.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Radiofrequency (RF) energy applied to breast cancers will result in cancer cell death. METHODS Prospective nonrandomized interventional trial. METHODS A university hospital tertiary care center. METHODS Five women with locally advanced invasive breast cancer, aged 38 to 66 years, who were

Pilot study of radiofrequency ablation therapy without surgical excision for T1 breast cancer: evaluation with MRI and vacuum-assisted core needle biopsy and safety management.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND There is increasing demand for minimally invasive treatments for small breast cancer mainly because of the desire for better cosmetic results. Although radiofrequency ablation (RFA) is an attractive approach as a local control method for small breast cancer, the problems of histological

Histopathological effect of radiofrequency ablation therapy for primary breast cancer, with special reference to changes in cancer cells and stromal structure and a comparison with enzyme histochemistry.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Radiofrequency ablation (RFA) therapy is expected to be applicable to small breast cancers, but no criteria for its histopathological effect have yet been established. Using samples obtained from 15 patients who had undergone RFA and subsequent mastectomy, we compared the histopathological changes

Radiofrequency ablation of small breast cancer followed by surgical resection.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND With the growing demand from patients for less-invasive procedures, the shift from surgical extirpation to ablative local control of breast tumors is an emerging focus in breast cancer care. This study was performed to determine the feasibility and safety of treating small breast cancer

Radiofrequency thermal ablation of breast cancer local recurrence: a phase II clinical trial.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND The role of radiofrequency (RF) ablation to treat local recurrence of breast cancer is unknown. METHODS We conducted a two-stage phase II clinical trial. Eligible patients had a histologically confirmed noninflammatory and < or =3 cm ipsilateral breast tumor recurrence. The tumor site was

Radiofrequency ablation therapy for small breast cancer followed by immediate surgical resection or delayed mammotome excision.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND There is increasing demand for minimally invasive treatment approaches. Although radiofrequency (RF) ablation therapy is promising for the local treatment of small, well-localized breast cancer, the problem of determining tumor cell death after RF ablation remains. METHODS In the first

Feasibility study on radiofrequency ablation followed by partial mastectomy for stage I breast cancer patients.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

To evaluate the safety and reliability of thermal ablation therapy instead of breast-conserving surgery (BCS), we performed radiofrequency ablation (RFA) for clinical stage I breast cancer patients. Subjects were T1N0 breast cancer patients with no extensive intraductal components. Under general

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye